{
    "organizations": [],
    "uuid": "a933fd7bfee8a18d21b987a0f84bd1e679a64d6e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-pacific-biosciences-posts-favorabl/brief-pacific-biosciences-posts-favorable-outcome-in-uk-and-german-patent-litigation-against-oxford-nanopore-idUSFWN1SF1BD",
    "ord_in_thread": 0,
    "title": "BRIEF-Pacific Biosciences Posts Favorable Outcome In UK And German Patent Litigation Against Oxford Nanopore",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Pacific Biosciences of California Inc :\n* PACIFIC BIOSCIENCES ANNOUNCES FAVORABLE OUTCOME IN UK AND GERMAN PATENT LITIGATION AGAINST OXFORD NANOPORE\n* PACIFIC BIOSCIENCES OF CALIFORNIA - AS PER OUTCOME, OXFORD NANOPORE WILL REFRAIN FROM OFFERING “2D” SEQUENCING PRODUCTS THROUGH END OF 2023 IN UK & GERMANY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T05:45:00.000+03:00",
    "crawled": "2018-05-09T12:24:12.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "pacific",
        "bioscience",
        "california",
        "inc",
        "pacific",
        "bioscience",
        "announces",
        "favorable",
        "outcome",
        "uk",
        "german",
        "patent",
        "litigation",
        "oxford",
        "nanopore",
        "pacific",
        "bioscience",
        "california",
        "per",
        "outcome",
        "oxford",
        "nanopore",
        "refrain",
        "offering",
        "2d",
        "sequencing",
        "product",
        "end",
        "uk",
        "germany",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}